LEZIL-M 60ML Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
LEZIL-M
Montelukast 4mg + Levocetirizine Dihydrochloride 2.5mg
LEZIL-M 60ML provides synergistic dual-pathway antiallergic relief by inhibiting histamine-induced peripheral symptoms and blocking cysteinyl leukotriene-mediated airway inflammation.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Selectively antagonizes peripheral H1 histamine receptors while competitively blocking leukotriene D4 receptors in respiratory and dermal pathways.
Usually 1 tablet once daily, preferably administered in the evening or at bedtime.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C. Do not freeze. Keep container tightly closed.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
LEZIL-M features Montelukast 4mg + Levocetirizine Dihydrochloride 2.5mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Reviewed through extensive post-mar for LEZIL-M 60ML
LEZIL-M 60ML has been reviewed through extensive post-marketing observational feedback, maintaining uniform therapeutic effectiveness from the first dose through completion. Packaging standards fully mirror WHO-GMP specifications, providing confidence to stocking chemists. We consider Sygnus Biotech a dependable manufacturing partner with genuinely high standards.
Questions Regarding LEZIL-M
What is the therapeutic indication and composition of LEZIL-M 60ML?
LEZIL-M 60ML contains Montelukast 4mg + Levocetirizine Dihydrochloride 2.5mg indicated for Allergic Rhinitis as formulated by Sygnus Biotech.
What packaging presentations are available for LEZIL-M 60ML?
LEZIL-M 60ML is supplied in tamper-evident 100ml / 200ml PET Bottle with Graduated Measuring Cap, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for LEZIL-M 60ML?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for LEZIL-M 60ML along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
LEZIL-M 60ML is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
